Merck touts new data for breakthrough pneumococcal vaccine as it heads to PhIII trials
Two months after Merck’s pneumococcal vaccine candidate V116 won breakthrough therapy designation based on Phase I/II trial data, Merck is now starting to share data from that study — touting topline results as the Big Pharma pushes to Phase III clinical trials.
Merck reported Tuesday that V116 showed non-inferior and superior immune responses, depending on the serotype, in hundreds of adult patients in the Phase II portion of the study. For shared serotypes with Merck’s older vaccine, Pneumovax 23, the responses were non-inferior. But for those not in the older shot, responses were superior, Merck said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.